抗肿瘤抗体偶联药物靶向递送的研究进展
Advances in the Targeted Delivery of Antibody Drug Conjugates
吴林霏 1胡珊珊 1黄嘉敏 1沈红璋 2张筱凤2
作者信息
- 1. 浙江中医药大学第四临床医学院,杭州 310005
- 2. 杭州市第一人民医院消化内科,杭州 310005
- 折叠
摘要
抗体与抗原结合的靶向递送是一种精准的递药方式,由于其高特异性和亲和力被视为理想的靶向递药方式之一,这为成功解决抗肿瘤治疗中化疗药物选择性差的问题开辟了新的道路.当前,利用单克隆抗体与靶抗原结合的抗体偶联药物(antibody drug conjugates,ADCs)研究成为分子靶向治疗的研究热点,本文就ADCs靶向递送的作用机制、靶向策略和靶向递送进展进行综述,以期为临床开发新的ADCs提供参考.
Abstract
Targeted delivery of antibody bound to antigen is a precise drug delivery mode.It is regarded as one of the ideal targeted drug delivery modes due to its high specificity and affinity,which opens up a new way to successfully solve the problem of poor selectivity of chemotherapy drugs in antitumor therapy.Currently,the research on antibody drug conjugates(ADCs)that bind monoclonal antibodies to target antigens has become a research hotspot of molecular targeted therapy.This paper reviews the mechanism of action,targeting strategies and progress in the targeted delivery of ADCs,in order to provide reference for the clinical development of new ADCs.
关键词
靶向递送/抗体偶联药物/恶性肿瘤/治疗/进展Key words
targeted delivery/antibody drug conjugates/malignant tumor/treatment/progress引用本文复制引用
基金项目
国家自然科学基金(82304628)
浙江省自然科学基金(LQ23H160047)
浙江省医药卫生科技计划(WKJ-ZJ-2136)
出版年
2024
NETL
NSTL
万方数据